

## Nigeria

### Support for Vaccine: Measles

#### This Decision Letter sets out the Programme Terms of a Programme

- 
1. **Country:** Nigeria
- 
2. **Vaccine grant number:** NGA-M-R-1&2
- 
3. **Date of Decision Letter:** 14 September 2021
- 
4. **Date of the Partnership Framework Agreement:** 09 January 2014
- 
5. **Programme title:** New Vaccine Support (NVS), Measles, 2-dose Routine
- 
6. **Vaccine type:** Measles
- 
7. **Requested product presentation and formulation of vaccine:**
- 
8. **Programme duration:**<sup>1</sup> 2019-2021

- 
9. **Programme Budget (indicative):**<sup>2</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)

	2019-2021	2022	2023	2024	2025	2026	Total <sup>2</sup>
Programme Budget(US\$)	8.915.548	-	-	-	-	-	8.915.548

- 
10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2019	NGA-M-R-1&2-VIG	20.173
2019	NGA-M-R-1&2-VIG-UNIC	360.834
2019	NGA-M-R-1&2-VIG-WHO	1.298.997
2020	NGA-M-R-1&2-VIG	10.619

<sup>1</sup>This is the entire duration of the programme.

<sup>2</sup>This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

<sup>3</sup>This is the amount that Gavi has approved.

2020	NGA-M-R-1&2-VIG-UNIC	462.908
2020	NGA-M-R-1&2-VIG-WHO	1.870.809

**11. Product switch grant:**

Not applicable

**12. Indicative annual amounts:<sup>3</sup>**

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2019-2021	2022	2023
Number of vaccine doses	-	-	-
Number of AD syringes	-	-	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	-	-
Annual Amounts (US\$)	8.915.548	-	-

**13. Procurement agency:**

Not applicable

**14. Self-procurement:**

Self-procurement applies. Please refer to the Partnership Framework Agreement terms and conditions.

**15. Co-financing obligations:**

Not applicable

**16. Operational support for campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>● vaccine stock levels including buffer stock, by end of March;</li> <li>● number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>● Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March</p> <p>15 May</p>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
---	------------------------------------

---

**18. Financial clarifications:**

Not applicable

---

**19. Other conditions:**

Not applicable